

Global Antibody-radionuclide Conjugates Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/GCEBA99FC8CFEN.html>

Date: October 2024

Pages: 153

Price: US\$ 3,200.00 (Single User License)

ID: GCEBA99FC8CFEN

Abstracts

Report Overview

Antibody-radionuclide Conjugates is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

The global Antibody-radionuclide Conjugates market size was estimated at USD 1042.80 million in 2023 and is projected to reach USD 4417.88 million by 2032, exhibiting a CAGR of 17.40% during the forecast period.

North America Antibody-radionuclide Conjugates market size was estimated at USD 358.82 million in 2023, at a CAGR of 14.91% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Antibody-radionuclide Conjugates market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the

Global Antibody-radionuclide Conjugates Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Antibody-radionuclide Conjugates market in any manner.

Global Antibody-radionuclide Conjugates Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Bayer

Novartis

Lantheus

Aurobindo Pharma

Mundipharma

China Isotope & Radiation

Curium Pharmaceuticals

Gilead Sciences

Clarity Pharmaceuticals

Curasight

Nordic Nanovector

Philogen

RadioMedix

Telix Pharmaceuticals

Orano Med

Actinium Pharmaceuticals

Y-mAbs Therapeutics

Fusion Pharmaceuticals

Market Segmentation (by Type)

Beta-emitting

Targeted Alpha Therapy

Market Segmentation (by Application)

Solid Tumor

Non Hodgkin Lymphoma

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Antibody-radionuclide Conjugates Market

Overview of the regional outlook of the Antibody-radionuclide Conjugates Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antibody-radionuclide Conjugates Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Antibody-radionuclide Conjugates, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share,

product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Antibody-radionuclide Conjugates

1.2 Key Market Segments

1.2.1 Antibody-radionuclide Conjugates Segment by Type

1.2.2 Antibody-radionuclide Conjugates Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Antibody-radionuclide Conjugates Market Size (M USD) Estimates and Forecasts (2019-2032)

2.1.2 Global Antibody-radionuclide Conjugates Sales Estimates and Forecasts (2019-2032)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET COMPETITIVE LANDSCAPE

3.1 Global Antibody-radionuclide Conjugates Sales by Manufacturers (2019-2024)

3.2 Global Antibody-radionuclide Conjugates Revenue Market Share by Manufacturers (2019-2024)

3.3 Antibody-radionuclide Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Antibody-radionuclide Conjugates Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Antibody-radionuclide Conjugates Sales Sites, Area Served, Product Type

3.6 Antibody-radionuclide Conjugates Market Competitive Situation and Trends

3.6.1 Antibody-radionuclide Conjugates Market Concentration Rate

3.6.2 Global 5 and 10 Largest Antibody-radionuclide Conjugates Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 ANTIBODY-RADIONUCLIDE CONJUGATES INDUSTRY CHAIN ANALYSIS

4.1 Antibody-radionuclide Conjugates Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF ANTIBODY-RADIONUCLIDE CONJUGATES MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

6 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Antibody-radionuclide Conjugates Sales Market Share by Type (2019-2024)

6.3 Global Antibody-radionuclide Conjugates Market Size Market Share by Type (2019-2024)

6.4 Global Antibody-radionuclide Conjugates Price by Type (2019-2024)

7 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Antibody-radionuclide Conjugates Market Sales by Application (2019-2024)

7.3 Global Antibody-radionuclide Conjugates Market Size (M USD) by Application

(2019-2024)

7.4 Global Antibody-radionuclide Conjugates Sales Growth Rate by Application
(2019-2024)

8 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET CONSUMPTION BY REGION

8.1 Global Antibody-radionuclide Conjugates Sales by Region

8.1.1 Global Antibody-radionuclide Conjugates Sales by Region

8.1.2 Global Antibody-radionuclide Conjugates Sales Market Share by Region

8.2 North America

8.2.1 North America Antibody-radionuclide Conjugates Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Antibody-radionuclide Conjugates Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Antibody-radionuclide Conjugates Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Antibody-radionuclide Conjugates Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Antibody-radionuclide Conjugates Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET PRODUCTION BY REGION

9.1 Global Production of Antibody-radionuclide Conjugates by Region (2019-2024)

9.2 Global Antibody-radionuclide Conjugates Revenue Market Share by Region (2019-2024)

9.3 Global Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Antibody-radionuclide Conjugates Production

9.4.1 North America Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)

9.4.2 North America Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Antibody-radionuclide Conjugates Production

9.5.1 Europe Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)

9.5.2 Europe Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Antibody-radionuclide Conjugates Production (2019-2024)

9.6.1 Japan Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)

9.6.2 Japan Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Antibody-radionuclide Conjugates Production (2019-2024)

9.7.1 China Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)

9.7.2 China Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)

10 KEY COMPANIES PROFILE

10.1 Bayer

10.1.1 Bayer Antibody-radionuclide Conjugates Basic Information

10.1.2 Bayer Antibody-radionuclide Conjugates Product Overview

10.1.3 Bayer Antibody-radionuclide Conjugates Product Market Performance

10.1.4 Bayer Business Overview

10.1.5 Bayer Antibody-radionuclide Conjugates SWOT Analysis

10.1.6 Bayer Recent Developments

10.2 Novartis

10.2.1 Novartis Antibody-radionuclide Conjugates Basic Information

- 10.2.2 Novartis Antibody-radionuclide Conjugates Product Overview
- 10.2.3 Novartis Antibody-radionuclide Conjugates Product Market Performance
- 10.2.4 Novartis Business Overview
- 10.2.5 Novartis Antibody-radionuclide Conjugates SWOT Analysis
- 10.2.6 Novartis Recent Developments
- 10.3 Lantheus
 - 10.3.1 Lantheus Antibody-radionuclide Conjugates Basic Information
 - 10.3.2 Lantheus Antibody-radionuclide Conjugates Product Overview
 - 10.3.3 Lantheus Antibody-radionuclide Conjugates Product Market Performance
 - 10.3.4 Lantheus Antibody-radionuclide Conjugates SWOT Analysis
 - 10.3.5 Lantheus Business Overview
 - 10.3.6 Lantheus Recent Developments
- 10.4 Aurobindo Pharma
 - 10.4.1 Aurobindo Pharma Antibody-radionuclide Conjugates Basic Information
 - 10.4.2 Aurobindo Pharma Antibody-radionuclide Conjugates Product Overview
 - 10.4.3 Aurobindo Pharma Antibody-radionuclide Conjugates Product Market Performance
 - 10.4.4 Aurobindo Pharma Business Overview
 - 10.4.5 Aurobindo Pharma Recent Developments
- 10.5 Mundipharma
 - 10.5.1 Mundipharma Antibody-radionuclide Conjugates Basic Information
 - 10.5.2 Mundipharma Antibody-radionuclide Conjugates Product Overview
 - 10.5.3 Mundipharma Antibody-radionuclide Conjugates Product Market Performance
 - 10.5.4 Mundipharma Business Overview
 - 10.5.5 Mundipharma Recent Developments
- 10.6 China Isotope and Radiation
 - 10.6.1 China Isotope and Radiation Antibody-radionuclide Conjugates Basic Information
 - 10.6.2 China Isotope and Radiation Antibody-radionuclide Conjugates Product Overview
 - 10.6.3 China Isotope and Radiation Antibody-radionuclide Conjugates Product Market Performance
 - 10.6.4 China Isotope and Radiation Business Overview
 - 10.6.5 China Isotope and Radiation Recent Developments
- 10.7 Curium Pharmaceuticals
 - 10.7.1 Curium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
 - 10.7.2 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
 - 10.7.3 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance

- 10.7.4 Curium Pharmaceuticals Business Overview
- 10.7.5 Curium Pharmaceuticals Recent Developments
- 10.8 Gilead Sciences
 - 10.8.1 Gilead Sciences Antibody-radionuclide Conjugates Basic Information
 - 10.8.2 Gilead Sciences Antibody-radionuclide Conjugates Product Overview
 - 10.8.3 Gilead Sciences Antibody-radionuclide Conjugates Product Market Performance
 - 10.8.4 Gilead Sciences Business Overview
 - 10.8.5 Gilead Sciences Recent Developments
- 10.9 Clarity Pharmaceuticals
 - 10.9.1 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
 - 10.9.2 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
 - 10.9.3 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
 - 10.9.4 Clarity Pharmaceuticals Business Overview
 - 10.9.5 Clarity Pharmaceuticals Recent Developments
- 10.10 Curasight
 - 10.10.1 Curasight Antibody-radionuclide Conjugates Basic Information
 - 10.10.2 Curasight Antibody-radionuclide Conjugates Product Overview
 - 10.10.3 Curasight Antibody-radionuclide Conjugates Product Market Performance
 - 10.10.4 Curasight Business Overview
 - 10.10.5 Curasight Recent Developments
- 10.11 Nordic Nanovector
 - 10.11.1 Nordic Nanovector Antibody-radionuclide Conjugates Basic Information
 - 10.11.2 Nordic Nanovector Antibody-radionuclide Conjugates Product Overview
 - 10.11.3 Nordic Nanovector Antibody-radionuclide Conjugates Product Market Performance
 - 10.11.4 Nordic Nanovector Business Overview
 - 10.11.5 Nordic Nanovector Recent Developments
- 10.12 Philogen
 - 10.12.1 Philogen Antibody-radionuclide Conjugates Basic Information
 - 10.12.2 Philogen Antibody-radionuclide Conjugates Product Overview
 - 10.12.3 Philogen Antibody-radionuclide Conjugates Product Market Performance
 - 10.12.4 Philogen Business Overview
 - 10.12.5 Philogen Recent Developments
- 10.13 RadioMedix
 - 10.13.1 RadioMedix Antibody-radionuclide Conjugates Basic Information
 - 10.13.2 RadioMedix Antibody-radionuclide Conjugates Product Overview
 - 10.13.3 RadioMedix Antibody-radionuclide Conjugates Product Market Performance

- 10.13.4 RadioMedix Business Overview
- 10.13.5 RadioMedix Recent Developments
- 10.14 Telix Pharmaceuticals
 - 10.14.1 Telix Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
 - 10.14.2 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
 - 10.14.3 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
 - 10.14.4 Telix Pharmaceuticals Business Overview
 - 10.14.5 Telix Pharmaceuticals Recent Developments
- 10.15 Orano Med
 - 10.15.1 Orano Med Antibody-radionuclide Conjugates Basic Information
 - 10.15.2 Orano Med Antibody-radionuclide Conjugates Product Overview
 - 10.15.3 Orano Med Antibody-radionuclide Conjugates Product Market Performance
 - 10.15.4 Orano Med Business Overview
 - 10.15.5 Orano Med Recent Developments
- 10.16 Actinium Pharmaceuticals
 - 10.16.1 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
 - 10.16.2 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
 - 10.16.3 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
 - 10.16.4 Actinium Pharmaceuticals Business Overview
 - 10.16.5 Actinium Pharmaceuticals Recent Developments
- 10.17 Y-mAbs Therapeutics
 - 10.17.1 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Basic Information
 - 10.17.2 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Overview
 - 10.17.3 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Market Performance
 - 10.17.4 Y-mAbs Therapeutics Business Overview
 - 10.17.5 Y-mAbs Therapeutics Recent Developments
- 10.18 Fusion Pharmaceuticals
 - 10.18.1 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
 - 10.18.2 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
 - 10.18.3 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
 - 10.18.4 Fusion Pharmaceuticals Business Overview
 - 10.18.5 Fusion Pharmaceuticals Recent Developments

11 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET FORECAST BY REGION

- 11.1 Global Antibody-radionuclide Conjugates Market Size Forecast
- 11.2 Global Antibody-radionuclide Conjugates Market Forecast by Region
 - 11.2.1 North America Market Size Forecast by Country
 - 11.2.2 Europe Antibody-radionuclide Conjugates Market Size Forecast by Country
 - 11.2.3 Asia Pacific Antibody-radionuclide Conjugates Market Size Forecast by Region
 - 11.2.4 South America Antibody-radionuclide Conjugates Market Size Forecast by Country
 - 11.2.5 Middle East and Africa Forecasted Consumption of Antibody-radionuclide Conjugates by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

- 12.1 Global Antibody-radionuclide Conjugates Market Forecast by Type (2025-2032)
 - 12.1.1 Global Forecasted Sales of Antibody-radionuclide Conjugates by Type (2025-2032)
 - 12.1.2 Global Antibody-radionuclide Conjugates Market Size Forecast by Type (2025-2032)
 - 12.1.3 Global Forecasted Price of Antibody-radionuclide Conjugates by Type (2025-2032)
- 12.2 Global Antibody-radionuclide Conjugates Market Forecast by Application (2025-2032)
 - 12.2.1 Global Antibody-radionuclide Conjugates Sales (K MT) Forecast by Application
 - 12.2.2 Global Antibody-radionuclide Conjugates Market Size (M USD) Forecast by Application (2025-2032)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

- Table 1. Introduction of the Type
- Table 2. Introduction of the Application
- Table 3. Market Size (M USD) Segment Executive Summary
- Table 4. Antibody-radionuclide Conjugates Market Size Comparison by Region (M USD)
- Table 5. Global Antibody-radionuclide Conjugates Sales (K MT) by Manufacturers (2019-2024)
- Table 6. Global Antibody-radionuclide Conjugates Sales Market Share by Manufacturers (2019-2024)
- Table 7. Global Antibody-radionuclide Conjugates Revenue (M USD) by Manufacturers (2019-2024)
- Table 8. Global Antibody-radionuclide Conjugates Revenue Share by Manufacturers (2019-2024)
- Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-radionuclide Conjugates as of 2022)
- Table 10. Global Market Antibody-radionuclide Conjugates Average Price (USD/MT) of Key Manufacturers (2019-2024)
- Table 11. Manufacturers Antibody-radionuclide Conjugates Sales Sites and Area Served
- Table 12. Manufacturers Antibody-radionuclide Conjugates Product Type
- Table 13. Global Antibody-radionuclide Conjugates Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 14. Mergers & Acquisitions, Expansion Plans
- Table 15. Industry Chain Map of Antibody-radionuclide Conjugates
- Table 16. Market Overview of Key Raw Materials
- Table 17. Midstream Market Analysis
- Table 18. Downstream Customer Analysis
- Table 19. Key Development Trends
- Table 20. Driving Factors
- Table 21. Antibody-radionuclide Conjugates Market Challenges
- Table 22. Global Antibody-radionuclide Conjugates Sales by Type (K MT)
- Table 23. Global Antibody-radionuclide Conjugates Market Size by Type (M USD)
- Table 24. Global Antibody-radionuclide Conjugates Sales (K MT) by Type (2019-2024)
- Table 25. Global Antibody-radionuclide Conjugates Sales Market Share by Type (2019-2024)

Table 26. Global Antibody-radionuclide Conjugates Market Size (M USD) by Type (2019-2024)

Table 27. Global Antibody-radionuclide Conjugates Market Size Share by Type (2019-2024)

Table 28. Global Antibody-radionuclide Conjugates Price (USD/MT) by Type (2019-2024)

Table 29. Global Antibody-radionuclide Conjugates Sales (K MT) by Application

Table 30. Global Antibody-radionuclide Conjugates Market Size by Application

Table 31. Global Antibody-radionuclide Conjugates Sales by Application (2019-2024) & (K MT)

Table 32. Global Antibody-radionuclide Conjugates Sales Market Share by Application (2019-2024)

Table 33. Global Antibody-radionuclide Conjugates Sales by Application (2019-2024) & (M USD)

Table 34. Global Antibody-radionuclide Conjugates Market Share by Application (2019-2024)

Table 35. Global Antibody-radionuclide Conjugates Sales Growth Rate by Application (2019-2024)

Table 36. Global Antibody-radionuclide Conjugates Sales by Region (2019-2024) & (K MT)

Table 37. Global Antibody-radionuclide Conjugates Sales Market Share by Region (2019-2024)

Table 38. North America Antibody-radionuclide Conjugates Sales by Country (2019-2024) & (K MT)

Table 39. Europe Antibody-radionuclide Conjugates Sales by Country (2019-2024) & (K MT)

Table 40. Asia Pacific Antibody-radionuclide Conjugates Sales by Region (2019-2024) & (K MT)

Table 41. South America Antibody-radionuclide Conjugates Sales by Country (2019-2024) & (K MT)

Table 42. Middle East and Africa Antibody-radionuclide Conjugates Sales by Region (2019-2024) & (K MT)

Table 43. Global Antibody-radionuclide Conjugates Production (K MT) by Region (2019-2024)

Table 44. Global Antibody-radionuclide Conjugates Revenue (US\$ Million) by Region (2019-2024)

Table 45. Global Antibody-radionuclide Conjugates Revenue Market Share by Region (2019-2024)

Table 46. Global Antibody-radionuclide Conjugates Production (K MT), Revenue (US\$

Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 47. North America Antibody-radionuclide Conjugates Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 48. Europe Antibody-radionuclide Conjugates Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 49. Japan Antibody-radionuclide Conjugates Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 50. China Antibody-radionuclide Conjugates Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 51. Bayer Antibody-radionuclide Conjugates Basic Information

Table 52. Bayer Antibody-radionuclide Conjugates Product Overview

Table 53. Bayer Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 54. Bayer Business Overview

Table 55. Bayer Antibody-radionuclide Conjugates SWOT Analysis

Table 56. Bayer Recent Developments

Table 57. Novartis Antibody-radionuclide Conjugates Basic Information

Table 58. Novartis Antibody-radionuclide Conjugates Product Overview

Table 59. Novartis Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 60. Novartis Business Overview

Table 61. Novartis Antibody-radionuclide Conjugates SWOT Analysis

Table 62. Novartis Recent Developments

Table 63. Lantheus Antibody-radionuclide Conjugates Basic Information

Table 64. Lantheus Antibody-radionuclide Conjugates Product Overview

Table 65. Lantheus Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 66. Lantheus Antibody-radionuclide Conjugates SWOT Analysis

Table 67. Lantheus Business Overview

Table 68. Lantheus Recent Developments

Table 69. Aurobindo Pharma Antibody-radionuclide Conjugates Basic Information

Table 70. Aurobindo Pharma Antibody-radionuclide Conjugates Product Overview

Table 71. Aurobindo Pharma Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 72. Aurobindo Pharma Business Overview

Table 73. Aurobindo Pharma Recent Developments

Table 74. Mundipharma Antibody-radionuclide Conjugates Basic Information

Table 75. Mundipharma Antibody-radionuclide Conjugates Product Overview

Table 76. Mundipharma Antibody-radionuclide Conjugates Sales (K MT), Revenue (M

USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 77. Mundipharma Business Overview

Table 78. Mundipharma Recent Developments

Table 79. China Isotope and Radiation Antibody-radionuclide Conjugates Basic Information

Table 80. China Isotope and Radiation Antibody-radionuclide Conjugates Product Overview

Table 81. China Isotope and Radiation Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 82. China Isotope and Radiation Business Overview

Table 83. China Isotope and Radiation Recent Developments

Table 84. Curium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information

Table 85. Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview

Table 86. Curium Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 87. Curium Pharmaceuticals Business Overview

Table 88. Curium Pharmaceuticals Recent Developments

Table 89. Gilead Sciences Antibody-radionuclide Conjugates Basic Information

Table 90. Gilead Sciences Antibody-radionuclide Conjugates Product Overview

Table 91. Gilead Sciences Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 92. Gilead Sciences Business Overview

Table 93. Gilead Sciences Recent Developments

Table 94. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Basic Information

Table 95. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Overview

Table 96. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 97. Clarity Pharmaceuticals Business Overview

Table 98. Clarity Pharmaceuticals Recent Developments

Table 99. Curasight Antibody-radionuclide Conjugates Basic Information

Table 100. Curasight Antibody-radionuclide Conjugates Product Overview

Table 101. Curasight Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 102. Curasight Business Overview

Table 103. Curasight Recent Developments

Table 104. Nordic Nanovector Antibody-radionuclide Conjugates Basic Information

Table 105. Nordic Nanovector Antibody-radionuclide Conjugates Product Overview

Table 106. Nordic Nanovector Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

- Table 107. Nordic Nanovector Business Overview
- Table 108. Nordic Nanovector Recent Developments
- Table 109. Philogen Antibody-radionuclide Conjugates Basic Information
- Table 110. Philogen Antibody-radionuclide Conjugates Product Overview
- Table 111. Philogen Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 112. Philogen Business Overview
- Table 113. Philogen Recent Developments
- Table 114. RadioMedix Antibody-radionuclide Conjugates Basic Information
- Table 115. RadioMedix Antibody-radionuclide Conjugates Product Overview
- Table 116. RadioMedix Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 117. RadioMedix Business Overview
- Table 118. RadioMedix Recent Developments
- Table 119. Telix Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
- Table 120. Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
- Table 121. Telix Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 122. Telix Pharmaceuticals Business Overview
- Table 123. Telix Pharmaceuticals Recent Developments
- Table 124. Orano Med Antibody-radionuclide Conjugates Basic Information
- Table 125. Orano Med Antibody-radionuclide Conjugates Product Overview
- Table 126. Orano Med Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 127. Orano Med Business Overview
- Table 128. Orano Med Recent Developments
- Table 129. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
- Table 130. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
- Table 131. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 132. Actinium Pharmaceuticals Business Overview
- Table 133. Actinium Pharmaceuticals Recent Developments
- Table 134. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Basic Information
- Table 135. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Overview
- Table 136. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 137. Y-mAbs Therapeutics Business Overview

- Table 138. Y-mAbs Therapeutics Recent Developments
- Table 139. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
- Table 140. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
- Table 141. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 142. Fusion Pharmaceuticals Business Overview
- Table 143. Fusion Pharmaceuticals Recent Developments
- Table 144. Global Antibody-radionuclide Conjugates Sales Forecast by Region (2025-2032) & (K MT)
- Table 145. Global Antibody-radionuclide Conjugates Market Size Forecast by Region (2025-2032) & (M USD)
- Table 146. North America Antibody-radionuclide Conjugates Sales Forecast by Country (2025-2032) & (K MT)
- Table 147. North America Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
- Table 148. Europe Antibody-radionuclide Conjugates Sales Forecast by Country (2025-2032) & (K MT)
- Table 149. Europe Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
- Table 150. Asia Pacific Antibody-radionuclide Conjugates Sales Forecast by Region (2025-2032) & (K MT)
- Table 151. Asia Pacific Antibody-radionuclide Conjugates Market Size Forecast by Region (2025-2032) & (M USD)
- Table 152. South America Antibody-radionuclide Conjugates Sales Forecast by Country (2025-2032) & (K MT)
- Table 153. South America Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
- Table 154. Middle East and Africa Antibody-radionuclide Conjugates Consumption Forecast by Country (2025-2032) & (Units)
- Table 155. Middle East and Africa Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
- Table 156. Global Antibody-radionuclide Conjugates Sales Forecast by Type (2025-2032) & (K MT)
- Table 157. Global Antibody-radionuclide Conjugates Market Size Forecast by Type (2025-2032) & (M USD)
- Table 158. Global Antibody-radionuclide Conjugates Price Forecast by Type (2025-2032) & (USD/MT)
- Table 159. Global Antibody-radionuclide Conjugates Sales (K MT) Forecast by

Application (2025-2032)

Table 160. Global Antibody-radionuclide Conjugates Market Size Forecast by
Application (2025-2032) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Antibody-radionuclide Conjugates
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Antibody-radionuclide Conjugates Market Size (M USD), 2019-2032
- Figure 5. Global Antibody-radionuclide Conjugates Market Size (M USD) (2019-2032)
- Figure 6. Global Antibody-radionuclide Conjugates Sales (K MT) & (2019-2032)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Antibody-radionuclide Conjugates Market Size by Country (M USD)
- Figure 11. Antibody-radionuclide Conjugates Sales Share by Manufacturers in 2023
- Figure 12. Global Antibody-radionuclide Conjugates Revenue Share by Manufacturers in 2023
- Figure 13. Antibody-radionuclide Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
- Figure 14. Global Market Antibody-radionuclide Conjugates Average Price (USD/MT) of Key Manufacturers in 2023
- Figure 15. The Global 5 and 10 Largest Players: Market Share by Antibody-radionuclide Conjugates Revenue in 2023
- Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 17. Global Antibody-radionuclide Conjugates Market Share by Type
- Figure 18. Sales Market Share of Antibody-radionuclide Conjugates by Type (2019-2024)
- Figure 19. Sales Market Share of Antibody-radionuclide Conjugates by Type in 2023
- Figure 20. Market Size Share of Antibody-radionuclide Conjugates by Type (2019-2024)
- Figure 21. Market Size Market Share of Antibody-radionuclide Conjugates by Type in 2023
- Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 23. Global Antibody-radionuclide Conjugates Market Share by Application
- Figure 24. Global Antibody-radionuclide Conjugates Sales Market Share by Application (2019-2024)
- Figure 25. Global Antibody-radionuclide Conjugates Sales Market Share by Application in 2023
- Figure 26. Global Antibody-radionuclide Conjugates Market Share by Application (2019-2024)

Figure 27. Global Antibody-radionuclide Conjugates Market Share by Application in 2023

Figure 28. Global Antibody-radionuclide Conjugates Sales Growth Rate by Application (2019-2024)

Figure 29. Global Antibody-radionuclide Conjugates Sales Market Share by Region (2019-2024)

Figure 30. North America Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 31. North America Antibody-radionuclide Conjugates Sales Market Share by Country in 2023

Figure 32. U.S. Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 33. Canada Antibody-radionuclide Conjugates Sales (K MT) and Growth Rate (2019-2024)

Figure 34. Mexico Antibody-radionuclide Conjugates Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 36. Europe Antibody-radionuclide Conjugates Sales Market Share by Country in 2023

Figure 37. Germany Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 38. France Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 39. U.K. Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 40. Italy Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 41. Russia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 42. Asia Pacific Antibody-radionuclide Conjugates Sales and Growth Rate (K MT)

Figure 43. Asia Pacific Antibody-radionuclide Conjugates Sales Market Share by Region in 2023

Figure 44. China Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 45. Japan Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 46. South Korea Antibody-radionuclide Conjugates Sales and Growth Rate

(2019-2024) & (K MT)

Figure 47. India Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 48. Southeast Asia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 49. South America Antibody-radionuclide Conjugates Sales and Growth Rate (K MT)

Figure 50. South America Antibody-radionuclide Conjugates Sales Market Share by Country in 2023

Figure 51. Brazil Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 52. Argentina Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 53. Columbia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 54. Middle East and Africa Antibody-radionuclide Conjugates Sales and Growth Rate (K MT)

Figure 55. Middle East and Africa Antibody-radionuclide Conjugates Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 57. UAE Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 58. Egypt Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 59. Nigeria Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 60. South Africa Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)

Figure 61. Global Antibody-radionuclide Conjugates Production Market Share by Region (2019-2024)

Figure 62. North America Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)

Figure 63. Europe Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)

Figure 64. Japan Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)

Figure 65. China Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)

Figure 66. Global Antibody-radionuclide Conjugates Sales Forecast by Volume (2019-2032) & (K MT)

Figure 67. Global Antibody-radionuclide Conjugates Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Antibody-radionuclide Conjugates Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Antibody-radionuclide Conjugates Market Share Forecast by Type (2025-2032)

Figure 70. Global Antibody-radionuclide Conjugates Sales Forecast by Application (2025-2032)

Figure 71. Global Antibody-radionuclide Conjugates Market Share Forecast by Application (2025-2032)

I would like to order

Product name: Global Antibody-radionuclide Conjugates Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/GCEBA99FC8CFEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCEBA99FC8CFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

